Literature DB >> 25072677

Factors affecting noncompliance with buprenorphine maintenance treatment.

Ayman Fareed1, Pamela Eilender, Bethany Ketchen, Ann Marie Buchanan-Cummings, Kelly Scheinberg, Kelli Crampton, Abigail Nash, Hilaire Shongo-Hiango, Karen Drexler.   

Abstract

BACKGROUND: The current study aimed to identify risk factors for treatment noncompliance in a sample of veterans receiving buprenorphine/naloxone for an opioid use disorder.
METHODS: Records from all patients who are currently or had previously been maintained on buprenorphine in the buprenorphine maintenance treatment program at the Atlanta VA Medical Center during the years 2006 to 2013 were evaluated. Of the 209 patients treated in the clinic between 2006 and 2013, 140 were excluded from the study because they did not have a call-back done at the time of data collection. Thus, 69 patient charts were selected for review.
RESULTS: The multiple linear regression analysis of the predictable variables for noncompliance with the buprenorphine pill count showed that positive urine drug screen (UDS) for marijuana, benzodiazepines, and being a smoker (F = 3.08; P = 0.03) are significantly associated with noncompliance with buprenorphine pill count.Also, the multiple linear regression analysis of the predictable variables for noncompliance with the buprenorphine pill count showed that the psychiatric comorbidity independently (F = 4.88; P = 0.03) is significantly associated with noncompliance with buprenorphine pill count.
CONCLUSIONS: Patients found to be noncompliant were more likely to suffer from comorbid psychiatric illness. Patients who tested positive for benzodiazepines or cannabis were more likely to be noncompliant with treatment. Although the rate of noncompliance (inaccurate pill count) was high, patients were still found to be taking their prescribed buprenorphine as evidenced by positive UDS for buprenorphine/norbuprenorphine. In addition, our sample had a high rate of negative UDS screens for opioids and cocaine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25072677     DOI: 10.1097/ADM.0000000000000057

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  14 in total

1.  Long-term retention in Office Based Opioid Treatment with buprenorphine.

Authors:  Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2016-12-30

2.  Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.

Authors:  Zoe M Weinstein; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong Kim; Gabriela Gryczynski; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2016-11-05       Impact factor: 4.492

3.  Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.

Authors:  John R Brooklyn; Stacey C Sigmon
Journal:  J Addict Med       Date:  2017 Jul/Aug       Impact factor: 3.702

4.  Buprenorphine and its formulations: a comprehensive review.

Authors:  Salomon Poliwoda; Nazir Noor; Jack S Jenkins; Cain W Stark; Mattie Steib; Jamal Hasoon; Giustino Varrassi; Ivan Urits; Omar Viswanath; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-08-20

5.  Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder.

Authors:  Jason B Gibbons; Jeffrey S McCullough; Kara Zivin; Zach Y Brown; Edward C Norton
Journal:  JAMA Psychiatry       Date:  2022-10-05       Impact factor: 25.911

6.  The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders.

Authors:  Elizabeth C Saunders; Mark P McGovern; Chantal Lambert-Harris; Andrea Meier; Bethany McLeman; Haiyi Xie
Journal:  Am J Addict       Date:  2015-09-21

7.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

8.  Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management.

Authors:  Shannon R Kenney; Bradley J Anderson; Genie L Bailey; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2018-08-28

9.  Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis.

Authors:  Kevin Y Xu; Jacob T Borodovsky; Ned Presnall; Carrie M Mintz; Sarah M Hartz; Laura J Bierut; Richard A Grucza
Journal:  Am J Psychiatry       Date:  2021-03-03       Impact factor: 19.242

10.  Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers.

Authors:  Laura G Duncan; Sonia Mendoza; Helena Hansen
Journal:  J Addict Med Ther Sci       Date:  2015-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.